Patricia Inacio reports for Myeloma Research News that Celgene’s international Phase 2 trial testing investigational CAR T-cell therapy bb2121 for the treatment of relapsed or refractory multiple myeloma patients has completed patient recruitment.  The trial is sponsored by a collaboration of Celgene and Bluebird Bio. The KarMMa trial included 140 patients across the U.S., Canada and Europe who had received at least three prior myeloma therapies—including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody—and failed to respond to their last treatment.

Source: Myeloma Research News

Pin It on Pinterest